By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


SEARCH JOBS

Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

Key Statistics


Email: info@progenics.com
Ownership: Public

Web Site: Progenics
Employees:
Symbol: PGNX
 









Company News
Progenics (PGNX) Announces Positive Topline Results From Registrational Phase IIb Trial Of AZEDRA 3/30/2017 11:24:11 AM
Progenics (PGNX) Announces Positive Topline Results From Registrational Phase IIb Trial Of AZEDRA 3/30/2017 9:31:57 AM
Data From Phase II Study Of Progenics (PGNX)’ PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine 3/24/2017 8:08:56 AM
Progenics (PGNX) Announces Fourth Quarter And Full-Year 2016 Financial Results And Business Update 3/9/2017 10:28:48 AM
Progenics (PGNX) Announces Initiation Of A Phase I Clinical Trial Of Its PSMA-Targeted Therapeutic Candidate 1095 For The Treatment Of Metastatic Prostate Cancer 2/14/2017 11:21:45 AM
Progenics (PGNX) Announces Independent Committee’s Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404 12/27/2016 8:28:59 AM
Progenics (PGNX) Announces First Patient Dosed In Phase II/III Clinical Trial Of PSMA-Targeted PET/CT Imaging Agent PyL 12/7/2016 7:50:15 AM
Progenics (PGNX) Announces Third Quarter 2016 Financial Results And Business Update 11/7/2016 8:13:17 AM
Progenics (PGNX) Gets a $50 Million Infusion 11/7/2016 6:47:14 AM
Progenics (PGNX) Sets Third Quarter 2016 Financial Results Call For November 7 10/24/2016 8:03:28 AM
12345678910...
//-->